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ABSTRACT
Objectives To identify how frequently patient- reported 
outcomes (PROs) are used as primary and/or secondary 
outcomes in randomised controlled trials (RCTs) and to 
summarise what statistical methods are used for the 
analysis of PROs.
Design Comprehensive review.
Setting RCTs funded and published by the United 
Kingdom’s (UK) National Institute for Health Research 
(NIHR) Health Technology Assessment (HTA) Programme.
Data sources and eligibility HTA reports of RCTs 
published between January 1997 and December 2020 
were reviewed.
Data extraction Information relating to PRO use and 
analysis methods was extracted.
Primary and secondary outcome measures The 
frequency of using PROs as primary and/or secondary 
outcomes; statistical methods that were used for the 
analysis of PROs as primary outcomes.
Results In this review, 37.6% (114/303) of trials used 
PROs as primary outcomes, and 82.8% (251/303) of trials 
used PROs as secondary outcomes from 303 NIHR HTA 
reports of RCTs. In the 114 RCTs where the PRO was the 
primary outcome, the most used PRO was the Short- Form 
36 (8/114); the most popular methods for multivariable 
analysis were linear mixed model (45/114), linear 
regression (29/114) and analysis of covariance (13/114); 
logistic regression was applied for binary and ordinal 
outcomes in 14/114 trials; and the repeated measures 
analysis was used in 39/114 trials.
Conclusion The majority of trials used PROs as primary 
and/or secondary outcomes. Conventional methods such 
as linear regression are widely used, despite the potential 
violation of their assumptions. In recent years, there is an 
increasing trend of using complex models (eg, with mixed 
effects). Statistical methods developed to address these 
violations when analysing PROs, such as beta- binomial 
regression, are not routinely used in practice. Future 
research will focus on evaluating available statistical 
methods for the analysis of PROs.
INTRODUCTION
Patient- reported outcomes (PROs) are health 
or health- related outcomes of health inter-
ventions reported by patients themselves. 
PROs enable health researchers to measure, 
Strengths and limitations of this study
 ► Patient- reported outcomes (PROs) are increasingly 
used as clinical outcomes, and the use of appropri-
ate statistical methods will ensure reliable estimates 
are produced to support decision making.
 ► This review summarises the up- to- date statistical 
methods that have been used for the primary anal-
ysis of PROs in 114 randomised controlled trials 
published by the UK’s National Institute for Health 
Research (NIHR) Health Technology Assessment 
(HTA) journal between January 1997 and December 
2020, and it is the largest comprehensive review 
of trials on the use of PROs and the corresponding 
statistical methods for the analysis of PROs to date.
 ► Most studies apply conventional statistical methods 
(eg, linear regression) for the analysis of PROs de-
spite the potential violation of the model assump-
tions, and even though specialist statistical methods 
have been developed to solve this problem, these 
methods are rarely used in practice.
 ► There was a lack of explicit reporting of PROs in 
some trials. Although assumptions have been made 
based on the context where some required informa-
tion was not explicitly stated, it is possible the ex-
tracted data were inconsistent with the researchers’ 
intention.
 ► This study included only trials published in the NIHR 
HTA journal as the information relating to PROs in 
other journals are not reported in as much detail and 
the HTA journal intends to publish all NIHR- funded 
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analyse and compare clinical outcomes from the patient 
perspective and provide clinical effectiveness outcomes 
to support decision making. The descriptive and scoring 
system of a PRO can transform subjective descriptions of 
health to numerical scores in a range of dimensions,1 and 
this transformation quantifies and allows the statistical 
analysis of these health- related outcomes.
Randomised controlled trials (RCTs) are regarded 
as the gold standard for evaluating the effectiveness of 
interventions.2 3 The randomisation process in a well- 
conducted RCT can reduce the selection bias and allo-
cation bias, and inform the causality of the treatment on 
responses.4 These traits of RCTs can simplify the analysis 
of PRO data. However, the RCT methodology does not 
bypass the possible systematic error from sources such as 
invalid measurements (eg, poorly or mistakenly filled PRO 
forms, ceiling or floor effects of the PRO scales), publica-
tion bias or selective reporting of statistical analyses.
Despite these traits of RCTs, it can still be complex 
to analyse PRO data in RCT settings for the following 
reasons.
First, one PRO can generate multiple outcomes and 
can be reported in different forms—using different 
score types such as subscales or summary scores; gener-
ating quality- adjusted survivals (ie, the integration of 
the quality- of- life function over the observed period of 
survival, such as quality- adjusted life years); producing 
dichotomised outcomes (eg, proportion of responders 
with a PRO score above or below a particular prespecified 
value or cut- off); and producing ordinal outcomes using 
several cut- offs. The various forms can result in multiple 
endpoints, and potentially increase the complexity of 
analysing PRO data.
Second, PRO data are likely to be discrete, skewed 
and bounded (ie, with ceiling effect and floor effects).5 
When analysing PRO data using a general linear model 
(including t- test, analysis of variance (ANOVA), analysis 
of covariance (ANCOVA) and linear regression), there 
are a number of assumptions6:
1. The values of the outcome variable should have a 
Normal distribution for each value of the explanatory 
variable. This assumption means that the residuals are 
Normally distributed and should have a mean of 0.
2. Constant variance or homoscedasticity of the outcome 
variable at each value of the explanatory variable.
3. The relationship between the outcome variable and 
the explanatory variable should be linear.
4. Independent observations in the sample.
These assumptions such as Normality of residuals and 
linear relationship between the outcome independent 
variable and explanatory dependent variables are likely 
to be violated.7 8
Also, the application of statistical methods might vary 
according to PRO data and the aim of the statistical 
analysis, but these features (multidimensional, discrete, 
skewed and bounded) of PRO data may obscure the deci-
sion on what statistical methods need to be applied for 
the data analysis.
An inappropriate statistical analysis of PROs can result 
in unreliable estimands of clinical effectiveness and 
accordingly fail to provide accurate and robust results for 
decision making, with wider confidence intervals (CIs) or 
larger errors.9 10 For example, patients may fail to receive 
an effective treatment because this treatment is falsely 
shown not to be clinically effective based on inaccurate 
estimands; vice versa, patients may receive treatment 
which may potentially harm their health when unreli-
able evidence supports the use of this treatment. Thus, 
applying appropriate statistical methods for the anal-
ysis of PROs is crucial to reduce biases of estimands, to 
accurately evaluate clinical effectiveness and to support 
healthcare decision making.
This study aimed to first identify how frequently PROs 
have been used as primary or secondary clinical outcomes 
in reports of RCTs published in the UK’s National Insti-
tute for Health Research (NIHR) Health Technology Assess-
ment (HTA) journal, and second, when the PRO was the 
primary outcome for trial, to summarise the statistical 
methods used to analyse the outcome.
METHODS
Definition of a PRO
There are several definitions of a PRO. For the purpose 
of this review, a PRO measure was defined as a question-
naire that measures health or a health- related outcome as 
a result of health interventions reported by patients them-
selves without any interpretation by clinicians or any other 
proxies. A PRO is an umbrella term for outcomes used to 
measure patients’ perceptions of health- related quality of 
life (QoL), broader aspects of QoL, health status, satisfac-
tion with the treatment and health conditions.1 11–13
Trial identification
Reports of RCTs published in the UK’s NIHR HTA 
journal between 1 January 1997 and 31 December 2020 
that defined and reported a PRO as a clinical endpoint 
or outcome for the trial were systematically identified 
and reviewed. The HTA journal was chosen because, in 
comparison to major medical journals, the information 
related to the trial and the PROs are reported in more 
detail. Information related to the use of PROs included 
the frequency of using PROs as clinical outcomes; 
whether the PROs were used as primary and/or secondary 
outcomes; the characteristics of the PROs when they 
were used as primary outcomes; and when the PRO was 
the primary outcome, the statistical method used for 
the analysis of the PRO data. The identification of HTA 
reports of RCTs used the same search strategy as previous 
work.14 The selection of trials with PROs was conducted 
by one reviewer (YQ). Three reviewers (SW, RJ and 
LF) conducted quality assurance checks on 30% of the 
included papers after the data extraction was completed, 
and disagreements were discussed to achieve consensus.
Inclusion and exclusion criteria
The studies included in this review satisfied the following 
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randomised, (2) trials with at least one PRO as the 
primary outcome and (3) trials with the statistical anal-
ysis conducted for the PRO. Studies excluded from this 
review included cluster RCTs as these have specific statis-
tical issues, influenza trials as these rarely use PROs as 
clinical outcomes, adaptive or group sequential trials as 
these have different statistical issues that may influence 
the choice of analysis, and follow- on studies and pilot/
feasibility studies.
PROs identified in this review can be well- established 
measures from previous studies with feasibility, reliability 
and validity already tested, or self- developed measures by 
researchers for use in the trial. For studies with measures 
which were not clearly defined as a PRO in the trial, 
various methods were taken to identify whether the 
measure was categorised as a PRO, including retrieving 
the cited paper that developed the measure, identifying 
signal words such as ‘carers’ and ‘physicians’ for rating 
or assessing patients’ outcomes in the measure descrip-
tion, and referring to other papers that developed or 
applied the outcome measure. According to our defini-
tion of PROs, trials that recruited only patients, or trials 
that recruited both patients and proxies when patients 
were unable to complete PROs were included; trials that 
used only proxies as informants to complete the PROs 
were excluded in order to avoid the cases where clinicians 
respond to health outcome measures on the patients’ 
behalf.
Trials using the product of PROs, such as a dichotomised 
outcome and quality- adjusted survival, were included. 
Trials that used PROs only as primary cost- effectiveness 
outcomes but not as clinical primary outcomes were 
excluded. Even if the statistical methods were proposed, 
trials that did not actually conduct the statistical analysis 
were excluded.
Data extraction
The following information was extracted from the reports 
of the included trials:
1. Characteristics of the trials with PROs as primary 
outcomes, including the number of participants ran-
domised and analysed, the baseline and postrandomi-
sation assessment, the most frequently used PROs and 
special types of PROs (including patient satisfaction, 
preference- based and proxy- reported).
2. Statistical methods conducted for the primary analy-
sis of the PROs, including the study population, the 
specific statistical methods, the adjustment for baseline 
score or other covariates, involvement of random ef-
fects, robust standard errors (SEs) and bootstrapping 
techniques, repeated measures analysis, and strategies 
for missing data.
3. The quality of reporting PROs, including whether 
there is a clear definition or justification of the prima-
ry outcomes or primary endpoints, statistical methods 
and covariates.
For the purpose of this review, the statistical methods 
were broadly categorised into two categories: ‘univariable 
methods’ that do not adjust for any other covariates except 
the randomised group (eg, t- test, χ2 test and simple linear 
regression) and ‘multivariable methods’ that have one or 
more explanatory variables (eg, baseline score) in addi-
tion to the randomised group (eg, multiple linear regres-
sion). The multivariable methods were further classified 
according to the categories of generalized linear models 
(GzLM), including linear regression, ANCOVA, binary 
logistic regression, ordinal logistic regression, and their 
extensions for correlated responses such as models with 
coefficients estimated by generalized estimating equa-
tions (GEEs) and mixed effect models. Repeated meas-
ures analysis for PROs with more than one postbaseline 
assessments was classified into four categories: response 
feature analysis (ie, using summary measures, such as the 
area under the curve or postrandomisation mean score); 
generalized linear mixed models; GzLM with parameters 
estimated by GEE; and repeated measures ANOVA.5 15
Patient and public involvement
Patients and the public were not involved in any way in 
this study.
RESULTS
In total, 1356 reports were published by the HTA journal 
between 1 January 1997 and 31 December 2020, and 
928 reports were excluded after screening the titles 
and abstracts. In the remaining 428 reports, 125 were 
excluded for various reasons (figure 1). In the 303 
published individual RCTs, 37.6% (114/303) of trials 
used PROs as primary outcomes and 82.8% (251/303) of 
trials used PROs as secondary outcomes. Two trials with 
Figure 1 Flow diagram for the inclusion and exclusion of 
trials published in the Health Technology Assessment journal 
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PROs as primary outcomes were excluded as they were 
closed without conducting a statistical analysis of the data 
using the statistical methods that were proposed in the 
report.16 17 It should be noted that the first RCT with a 
PRO as a clinical outcome was published in the HTA 
journal in 1999,18 and the earlier reports published in the 
HTA journal were mainly systematic reviews.
All included trials that used PROs as primary outcomes 
also used PROs as secondary outcomes. The trend of 
using PROs as clinical outcomes in trials between 1999 
and 2020 is shown in figure 2. Except for the earlier years 
(1999–2003) with a small number of studies, the propor-
tion of trials with PROs used as secondary outcomes (the 
red curve) is approximately two times higher than the 
proportion of the trials with PROs as primary outcomes 
(the blue curve). Generally, there is an increase in using 
PROs as clinical outcomes in HTA trials.
Trial characteristics
In total, 83.1% (61 715/74 298) of the participants 
randomised in the 114 trials were used for the primary 
analysis (table 1). The characteristics of these trials are 
summarised in table 2. The most common design was a 
two- arm parallel group trial. More than half of the trials 
were in either mental health (30/114) or musculoskel-
etal conditions (28/114). Most trials collected baseline 
assessments (101/114) and more than one postbaseline 
assessments (107/114). The maximum number of post-
baseline assessments was 24 in a trial on eczema manage-
ment for children.19
Most trials (107/114) clearly defined the primary 
outcomes; the sample size calculation implied the 
primary outcomes for the trial was a PRO in six trials that 
did not explicitly specify the primary outcome, and one 
trial defined PROs as main outcome measures but used 
an alternative outcome for the sample size calculation.20 
Table 3 summarises the PROs used as primary outcomes 
in four or more included trials. The most popular PROs 
were mainly generic (ie, Short Form-36/Short Form 
6- Dimension (SF- 6D) and EuroQol-5 Dimension (EQ- 
5D)) and depression- specific (ie, Beck Depression Inven-
tory, Hospital Anxiety and Depression Scale and Patient 
Health Questionnaire). Eight trials used more than one 
PRO as the primary outcomes, and 14 trials used non- 
PRO clinical outcomes as coprimary outcomes.
Preference- based PROs were used in six trials as primary 
outcomes, including five21–25 that used the EQ- 5D and 
one26 that used the SF- 6D. Seven trials used the quality- 
adjusted survival, including three22 23 25 that used the 
EQ- 5D and four27–30 that used specific PROs for estima-
tion. Patient satisfaction was used as the primary outcome 
Figure 2 Number and proportion of trials using patient- reported outcomes (PROs) as primary and/or secondary outcomes 
from 1999 to 2020.
Table 1 Recruitment and retention of trial participants included from the 144 reports
Items Mean Median SD Min Max Total
Number of participants randomised 652 480 928 85 8003 74 298
Number of participants analysed* 541 388 847 65 7677 61 715
*Number of participants analysed in the primary analysis of patient- reported outcomes; if multiple postbaseline assessments were used for 
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in two trials.31 32 Proxies were recruited in six trials19 33–37 
that primarily aimed to collect PROs and only recruited 
proxies for patients who were unable to complete the 
PROs. Seven included trials used self- developed PROs 
as the primary or coprimary outcome. Most of these 
PROs had one item based on Likert Scale or Visual 
Analogue Scale (VAS), except for one trial38 that specially 
developed a REFLUX questionnaire with 31 items to 
generate the QoL of patients with gastro- oesophageal 
reflux disease. Health outcomes assessed by investigators 
were not included as primary outcomes, for example, 
four trials39–41 using the Quality of Life Scale or Rankin 
Scale, that were completely assessed by investigators were 
excluded.
Different score types were used to summarise the PRO 
primary outcomes. Most trials (98/114) used one score 
type to report the primary outcome, and the rest of the 
trials used two types of scores. Summary scores were the 
most popular way to measure PROs (83/114), followed by 
subscales (30/114) and single items (16/114), including 
Likert Scale (11/114) and VAS (5/114).
Statistical methods for the primary analysis of PROs
The majority of trials stated the proportion of missing 
PRO data (109/114), developed strategies to deal with 
missing data (99/114), imputed missing data using 
various methods such as mean imputation and last obser-
vation carried forward (89/114). In 40/114 studies, 
missing data were imputed as part of a sensitivity analysis 
to check the robustness of the primary analysis strategy 
which did not consider missing data.
Intention- to- treat (ITT) analysis (ie, analysis based on 
the randomised treatment assignment of all participants 
but not the actual treatment received),42 including ITT 
with and without missing data imputation, was used in 
111/114 trials, and 46 trials used other study popula-
tions such as per protocol analysis (ie, analysis based 
on the patients who completed the originally treatment 
Table 3 Most frequently used PROs as primary outcomes 
in the included trials
PROs Abbreviation No % Reference










HADS 5 4.4 84
EuroQol-5 
Dimension
EQ- 5D 5 4.4 85–87
Patient Health 
Questionnaire
PHQ 5 4.4 88
Oxford Shoulder 
Score
OSS 4 3.5 89
Other* 90 78.9
Total†   124 108.8   
*Only PROs that were used in four or more trials are listed 
separately.
†The total number of included trials is 114. Eight trials used more 
than one PRO as primary outcomes, including two trials that 
used three PROs and six trials that used two PROs as primary 
outcomes.
PRO, patient- reported outcome.
Table 2 Trial design and assessment characteristics of the 
114 trials included in the review
Items No % Total





















Number of trials 
with a baseline 
assessment of the 
patient- reported 
outcome





<1 month 7 6.0 114
1–6 months 28 23.9
>6–18 months 50 42.7












†Chronic fatigue, minor surgery, multiple sclerosis, neurosurgery, 
paediatric, sleep disorders, urology, vascular.
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assigned), as treated or complier average causal effect 
analysis (ie, analysis of the treatment effect based on 
the subgroup that completed the originally treatment 
assigned) for the secondary or sensitivity analysis.
The statistical methods applied for primary analyses 
were clearly defined in 79/114 trials, and the use of 
univariable or multivariable methods for primary analyses 
were justified in 92/114 trials. Except for two trials that 
did not specify the timing and number of postrandomi-
sation assessments,43 44 72/114 clearly defined the single 
timepoint used for the primary analysis (eg, x months 
postbaseline), and 40/114 used the repeated postbase-
line outcomes for the primary analysis.
The statistical methods used for the primary analysis 
of PROs are shown in table 4. The linear mixed model 
(45/114) and linear regression (29/114) and ANCOVA 
(13/114) were the most popular methods. Among the 45 
trials using linear mixed models for the primary analysis, 
23 trials conducted a repeated measures analysis, and the 
rest did not consider the repeated postbaseline outcomes 
in the primary analysis. Three trials used GzLM with coef-
ficients estimated by GEE for the longitudinal primary 
analysis, including one as an extension to ordinal logistic 
regression45 and two as an extension to linear regres-
sion.39 46 Only one trial with quality- adjusted survival used 
Cox regression for the primary analysis.25
Bootstrapped confidence intervals (CIs) were calcu-
lated after using a general linear model (including t-test, 
ANCOVA and linear regression) or linear mixed model 
in six trials18 20 22 37 47 48 due to the skewness of PRO scores, 
and one additional trial did not conduct any other statis-
tical analysis except calculating the bootstrapped CI for 
the treatment estimate.49 Robust SEs can be used to esti-
mate CIs and the calculation of test statistics (and asso-
ciated P- values). Six trials37 45 50–52 reported using robust 
SEs based on regression methods for the primary analysis, 
and three trials46 53 54 reported using robust SEs for the 
longitudinal analysis in the non- primary analysis.
There were 106 trials that used multivariable methods, 
of which 98 clearly reported the covariates adjusted in 
the primary analysis. Among them, 85 trials adjusted for 
baseline score of the PRO, and 3 trials55–57 modelled the 
change of PRO from baseline in the primary analysis. The 
use of random effects for the primary analysis of PROs was 
clearly specified in 47 trials: 44 used linear mixed models, 
and the other 3 trials used repeated measures ANOVA,58 
binary logistic mixed model27 and ordinal logistic mixed 
model,32 respectively. The most common random factors 
applied in the multivariable methods were therapists, 
centres (ie, hospital sites) and individual patients.
Trend of using statistical methods for the primary analysis of 
PROs
Figure 3 shows the trend of using different statistical 
methods over the observed period. There is an increasing 
trend for using more complex models (mixed models 
and GLzM with GEE) in most recent years for the anal-
ysis of PROs. Linear regression, ANCOVA and repeated 
Table 4 Statistical methods used for the main or primary 
analysis of PROs that are the primary outcomes of the trials
Statistical methods N % Total
Univariable methods     27
  t- test 11 40.7   
  Unadjusted 
regression methods*
7 25.9   
  χ2 test 3 11.1   
  Wilcoxon rank- sum 
test (Mann- Whitney 
U test)
4 14.8   
  Kruskal- Wallis test 1 3.7   
  Log- rank test 1 3.7   
Multivariable 
methods†
    106
  Linear mixed model 45 42.5   
  Linear regression 29 27.4   
  ANCOVA 13 12.3   
  Linear regression 
with GEE
2 1.9   
  Binary logistic 
regression
8 7.5   
  Binary logistic 
mixed model
1 0.9   
  Ordinal logistic 
regression
4 3.8   
  Ordinal logistic 
mixed model
1 0.9   
  Repeated measures 
ANOVA
6 5.7   




  Linear mixed model 23 59.0   
  Response feature 
analysis‡
7 17.9   
  Repeated measures 
ANOVA
6 15.4
  GzLM with GEE 3 7.7   
*In seven trials using unadjusted regression methods with no other 
covariates in the model besides the randomised group, three trials 
used linear regression; one used the linear mixed model; two used 
ordinal logistic regression; and one used binary logistic regression.
†106 trials used multivariable methods for the analysis of PROs, 
including 4 trials that used two different methods for the primary 
analysis of PROs.
‡In seven trials using response feature analysis (with quality- 
adjusted survivals) in primary analysis, four used linear regression 
or ANCOVA; two used linear mixed models; and one used survival 
analysis.
ANCOVA, analysis of covariance; ANOVA, analysis of variance; 
GEE, generalized estimating equation; GzLM, generalized linear 
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measures ANOVA were the most popular regression 
methods used from 1999 to 2010, used in around 63% 
of trials on average. However, this popularity dropped to 
28.6% during 2011–2015 and 30.0% during 2016–2020. 
In contrast, the proportion of trials using the linear mixed 
model and linear regression with GEE for correlated 
outcomes increased across the observation period, from 
11.1% to 54.0%. While the use of binary logistic regres-
sion slightly decreased from 11.1% to 4.0% over time, the 
proportion of trials using ordinal logistic regression for 
the primary analysis remained small.
DISCUSSION
This study has systematically conducted a review which 
summarised how frequently PROs have been used 
and what statistical methods have been applied for the 
primary analysis of PROs in RCTs published by the UK’s 
NIHR HTA journal between 1997 and 2020. This review 
found that 82.8% (251/303) used PROs as primary or 
secondary outcome, and 37.6% (114/303) used PROs as 
primary outcomes. Though conventional methods (such 
as t- test, multiple linear regression and ANCOVA) have 
been widely used, there is a growing trend of using more 
complex methods such as linear mixed models (with both 
fixed and random effects) for the analysis of PROs over 
the observed period of this review.
The general linear model (including t- test, ANOVA, 
ANCOVA and linear regression) and linear mixed model 
were widely used over the past two decades, which could 
possibly result from the frequent use of continuous data 
type of response variables. The trend of using complex 
models could result from the increasing complexity of 
trial designs and from recommendations on using linear 
mixed models over repeated measures ANOVA for the 
longitudinal analysis of PROs.5 59 There is a decrease 
in the use of binary logistic regression as the dichoto-
mised outcome gathers less information from the PROs 
compared with other score types.60
There is a gap between the statistical methods devel-
oped by methodologists and statistical methods used for 
the analysis of PROs in trials. For example, Arostegui 
et al recommend the use of ordinal logistic regression 
with random effects model, beta- binomial regression or 
beta- logit- normal regression for continuous or ordinal 
PRO data after testing distributional assumptions.59 61 
However, only one of the five included trials that used 
ordinal logistic regression for the primary analysis consid-
ered random effects.32 Neither beta- binomial regression 
nor beta- logit- normal regression were used by the 114 
trials. Interestingly, the international standards for the 
analysis of PROs in cancer trials by the SISAQOL (Setting 
International Standards in Analysing Patient- Reported 
Outcomes and Quality of Life Endpoints Data) Consor-
tium neither recommended the use of ordinal regression 
nor compared ordinal regression with other statistical 
methods.62 The conventional methods are popular since 
the estimands produced by simple models can remain 
Figure 3 Percentage of trials using multivariable methods for the primary analysis of PROs from 1999 to 2020
(N=xx) denotes the number of trials published in the specified period. As the survival analysis was used only in one trial, 
it is not shown in this graph. As this graph only summarised multivariable methods and one trial could use two or more 
multivariable methods for the primary analysis, the number of trials summarised in this graph may not equal the total 
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robust regardless of the violation of model assumptions.7 
In addition, the difficulty in applying newly developed 
models in statistical software and the complexity to 
explain estimands of these models may make researchers 
more reluctant to use them.
PRO outcomes tend to generate data with discrete, 
skewed and bounded distributions that are not Normally 
distributed, and the assumptions for statistical methods 
such as the t- test, linear regression and ANCOVA may not 
be valid. However, Heeren and D’Agostino63 have demon-
strated the robustness of the two independent samples t- 
test when applied to three- point, four- point and five- point 
ordinal scaled data using assigned scores, in sample sizes 
as small as 20 subjects per group. Sullivan and D’Agos-
tino64 have expanded this work to account for a covariate 
when the outcome is ordinal in nature. They again assign 
numeric scores to the distinct response categories and 
compare means between treatment groups adjusting for 
a covariate reflecting a baseline assessment measured on 
the same scale. Their simulation study shows that in the 
presence of three- point, four- point and five- point ordinal 
data and small sample sizes (as low as 20 per group), both 
ANCOVA and the two independent sample t- tests on 
difference scores are robust and produce actual signifi-
cance levels close to the nominal significance levels.
Furthermore, statistical theory says that if the distri-
bution of an outcome variable is Normal, so will be the 
distribution of the sample mean for that outcome vari-
able. Much more importantly, even if the distribution of 
the outcome is not Normal, that of the sample mean will 
become closer to the Normal distribution as the sample 
size gets larger. This is a consequence of the Central Limit 
Theorem. The Normal distribution is strictly only the 
limiting form of the sampling distribution as the sample 
size increases to infinity, but it provides a remarkably 
good approximation to the sampling distribution even 
when the sample size is small, and the distribution of the 
outcome variable is far from Normal.65 Thus, conventional 
statistical methods such as the t- test, linear regression/
ANCOVA for analysing PROs are robust to the violation 
of assumptions for moderate to large sample sizes.66
To the best of our knowledge, this study is by far the 
largest review of trials (with 114 studies) published by the 
HTA journal which analysed the frequency of using PROs 
and the statistical methods for the analysis of PROs. The 
reviews by Pe et al10 (breast cancer); Hamel et al9 (lung 
cancer) and Fiteni et al67 (lung cancer) had sample sizes 
of 66, 33, 27 articles, respectively. Compared with other 
reviews that concentrate on only one clinical area (ie, 
oncology),9 10 67–70 this review summarised details in the 
frequency of using PROs and applying statistical methods 
in RCTs with a range of clinical areas.
It is noteworthy that the proportions of trials using 
PROs reported in this review represent the average rate of 
HTA trials focusing on different clinical areas, and when 
considering specific disease(s) or selecting different 
database(s), the proportions may vary. For example, 
Pe et al10 identified 3/66 (5%) and 46/66 (70%) RCTs 
of locally advanced and metastatic breast cancer using 
PROs as primary and secondary endpoints, respectively. 
Marandino et al71 reviewed 446 cancer trials published 
in major journals between 2012 and 2016, and found 
that PRO or QoL was a primary endpoint in five trials 
(1.1%), a secondary endpoint in 195 trials (43.7%) and 
an exploratory endpoint in 36 trials (8.1%), while in the 
remaining 210 (47.1%), QoL was not listed at all among 
the study endpoints. Our review found that 3 of 18 cancer 
trials (17%) used PROs as primary outcomes, and 13/18 
(72%) used PROs as secondary outcomes. Our results 
showed that PROs were more frequently used for health 
problems such as mental and musculoskeletal diseases.
This study has the following limitations. First, this review 
looked only at publicly funded trials in the UK, which 
may represent a limitation in terms of the generalisability 
of the findings. It is possible that statistical methods 
are used differently in industry- funded trials or in trials 
in other countries. However, as the NIHR HTA journal 
intends to publish all NIHR- funded projects, it has less 
publication bias compared with journals that publish only 
positive outcomes, and the information related to PROs 
in other journals is not reported in as much detail. The 
extracted statistical methods for the analysis of PROs from 
this review are consistent with those included from other 
similar reviews.9 10 67–70 Second, there might be other 
appropriate methods for the analysis of PROs that were 
not included in this review. This review mainly analysed 
RCTs with PROs as primary outcomes because primary 
outcomes and the corresponding statistical methods were 
more explicitly reported.
Third, trials with PROs used only as cost- effectiveness 
outcomes were excluded. This is because the statistical 
strategies for clinical effectiveness and cost- effectiveness 
outcomes may vary, and cost- effectiveness analysis (CEA) 
produces both cost and clinical effectiveness outcomes. If 
PROs for CEA were included in this review, the propor-
tion of included trials would increase, as there were some 
studies using EQ- 5D for the primary CEA. It could be 
argued that the analysis of effectiveness estimated by PROs 
in CEA also requires appropriate statistical methods, but 
estimands calculated for a health economic analysis could 
be different from those for a clinical analysis as they hold 
different purposes to conduct these analyses. Therefore, 
we believe it is justified to make this exclusion.
We used a broad definition for a PRO, and a small 
number of trials (seven) used PROs that were specifically 
developed for the trial and were not validated in another 
external study. The inclusion of such non- validated instru-
ments as primary outcomes should be discouraged and 
may have affected the results, although the characteristics 
of these PROs (Likert Scale or VAS) are similar to those 
of the PROs that have been formally validated. We believe 
that it is not unreasonable to assume that the statistical 
analysis of such outcomes would be similar to the analysis 
of validated PROs.
Another potential limitation is the large time window, 
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some variability and potential heterogeneity in the trials 
included in the review, but on the positive side, it allows 
testing of time trends in the type of statistical methods 
used in the trials.
Last, the information related to PROs and statistical 
methods was not clearly reported in some trials. Although 
assumptions have been made based on the context where 
some required information was not explicitly stated, it is 
possible that the data extracted were inconsistent with 
researchers’ intention. However, as the data have been 
extracted for all reports by one reviewer, there is consis-
tency in the interpretation and assumptions made.
To produce explicit reports, it is recommended that 
researchers follow specific guidelines that can instruct the 
reporting of using PROs in RCT papers and protocols such 
as the CONSORT (Consolidated Standards of Reporting 
Trials) PRO (patient- reported outcomes) Extension,13 
SPIRIT (Standard Protocol Items: Recommendations for 
Interventional Trials) PRO (patient- reported outcome) 
Extension72 and the standards for the analysis of PROs 
in cancer RCTs.62 In addition, a clear classification of the 
terminology of the statistical methods is desired. It is a 
historical problem that the names of statistical methods 
are confusing (eg, general linear model vs GzLM), and 
multiple terms can be used to describe the same method; 
for example, the proportional odds model, ordered logit 
model and ordinal logistic regression refer to the same 
regression technique. Thus, researchers should be clear 
and cautious when describing the exact statistical method 
for the analysis.
In addition to the abovementioned issues, other obsta-
cles are also worth attention when analysing PROs in 
RCT settings, which can be broadly classified into three 
domains: first, the statistics domain—inadequate under-
standing of basic statistical concepts,73 incorrect proce-
dures used to carry out statistical analysis and incorrect 
statistical inference (eg, secretly hypothesising after 
results are known)74 75; second, the PROs domain—appli-
cation of invalid measurements,76 lack of comparability 
among the results produced by various PROs77; and the 
third domain, reporting and publishing—publication 
bias and selective reporting of trials and their associated 
outcomes.77 78
In conclusion, the majority of trials funded by the 
NIHR HTA Programme used PROs as primary and/or 
secondary outcomes. Although there is an increasing 
trend of using complex models (eg, mixed effects), 
conventional methods such as linear regression remain 
widely used for the analysis of PROs, despite the potential 
violation of their assumptions. Statistical methods devel-
oped to address these violations when analysing PROs, 
such as beta- binomial regression, are not routinely used 
in practice. Various methods for the analysis of PROs have 
been identified from this review, but it is still unknown 
which methods are the most appropriate for the analysis 
of PRO data. Future research will focus on evaluating 
available statistical methods and make recommendations 
on using different methods for the analysis of PRO data.
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